GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration-Reference-Cited by-同舟云学术

GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration

Published:2020-02-12 Issue:530 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ackeifi Courtney¹^ORCID,Wang Peng¹,Karakose Esra¹,Manning Fox Jocelyn E.²,González Bryan J.³^ORCID,Liu Hongtao¹,Wilson Jessica¹^ORCID,Swartz Ethan¹,Berrouet Cecilia¹,Li Yansui¹,Kumar Kunal⁴,MacDonald Patrick E.²^ORCID,Sanchez Roberto⁴,Thorens Bernard⁵,DeVita Robert⁴^ORCID,Homann Dirk¹^ORCID,Egli Dieter³,Scott Donald K.¹^ORCID,Garcia-Ocaña Adolfo¹^ORCID,Stewart Andrew F.¹^ORCID

Affiliation:

1. Diabetes, Obesity and Metabolism Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

2. Department of Pharmacology and Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.

3. Naomi Berrie Diabetes Center and Columbia Stem Cell Center, Columbia University, New York, NY 10032, USA.

4. Department of Pharmacological Sciences, and Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

5. Center for Integrative Genomics, University of Lausanne, Lausanne 1015, Switzerland.

Abstract

GLP-1 receptor agonists, widely used to treat diabetes, are converted to human β cell regenerative drugs by adding a DYRK1A inhibitor.

Funder

NIH Office of the Director

JDRF

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference44 articles.

1. World Health Organization Global Reports on Diabetes; www.who.int/diabetes/global-report/en/.

2. β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

3. Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes

4. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

5. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management;International Journal of Molecular Sciences;2024-08-29

2. Dual targeting of inflammation and β-cell dysfunction for therapy of diabetes mellitus;Journal of Drug Delivery Science and Technology;2024-08

3. Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment;Current Issues in Molecular Biology;2024-07-18

4. Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system;Science Translational Medicine;2024-07-10

5. Development, regeneration, and physiological expansion of functional β-cells: Cellular sources and regulators;Frontiers in Cell and Developmental Biology;2024-07-09